ReviewJournal of Cancer2016
Hepatocellular Carcinoma and Diffusion-Weighted MRI: Detection and Evaluation of Treatment Response.
Review in Journal of Cancer, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06168357 (Role of Abbreviated MRI in Follow-up of Hepatocellular Carcinoma Following Locoregional Treatment.), which is not on this map. Cited by 33 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Role of Abbreviated MRI in Follow-up of Hepatocellular Carcinoma Following Locoregional Treatment.
Who cites it
33 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Identifying the primary tumour in patients with cancer of unknown primary (CUP) using [European journal of nuclear medicine and molecular imaging · 2024Pooled it
- Pooled it
- Evaluating boost diffusion sampling for improved abdominal imaging using prototype slice-specific shimming method.Magma (New York, N.Y.) · 2026Article
- Loss of both diffusion restriction and arterial enhancement can predict complete pathological response following Y-90 selective internal radiation therapy for hepatocellular carcinoma.Abdominal radiology (New York) · 2026Article
- Advancing free-breathing liver diffusion-weighted imaging with Propeller-EPI: Improved image quality and ADC repeatability.Medical physics · 2025Article
- The nVR model: prediction of LI-RADS treatment response nonviable recurrence of hepatocellular carcinoma after primary transarterial chemoembolization.Abdominal radiology (New York) · 2025Article
- Effect of simultaneous multislice acceleration on the quantitative measurements of diffusion-weighted imaging, intravoxel incoherent motion, and diffusion kurtosis imaging in hepatocellular carcinoma and abdominal organs.Quantitative imaging in medicine and surgery · 2025Article
- Magnetic resonance imaging features of intrahepatic bile duct adenoma: a 10-year retrospective study.BMC medical imaging · 2025Article
- Distinguishing Hepatocellular Carcinoma from Cirrhotic Regenerative Nodules Using MR Cytometry.Cancers · 2025Article
- Standardizing diffusion-weighted imaging in LI-RADS for diagnosis of hepatocellular carcinoma.European radiology · 2025Article
- Beyond the Liver: A Comprehensive Review of Strategies to Prevent Hepatocellular Carcinoma.Journal of clinical medicine · 2024Review
- Article
- Quantitative diffusion weighted imaging in patients with hepatocellular carcinoma: effects of simultaneous multi-slice acceleration and gadoxetic acid administration.Abdominal radiology (New York) · 2024Article
- Role of gadoxetic acid-enhanced liver magnetic resonance imaging in the evaluation of hepatocellular carcinoma after locoregional treatment.World journal of gastroenterology · 2022Review
- Evaluation of non-contrast magnetic resonance imaging as an imaging surveillance tool for hepatocellular carcinoma in at-risk patients.Singapore medical journal · 2022Article
- Magnetic Fields and Cancer: Epidemiology, Cellular Biology, and Theranostics.International journal of molecular sciences · 2022Review
- Value of Intravoxel Incoherent Motion (IVIM) Imaging for Differentiation between Intrahepatic Cholangiocarcinoma and Hepatocellular Carcinoma.Contrast media & molecular imaging · 2022Article
- Evaluation of the efficacy of transcatheter arterial embolization combined with apatinib on rabbit VX2 liver tumors by intravoxel incoherent motion diffusion-weighted MR imaging.Frontiers in oncology · 2022Article
- Imaging biomarkers for evaluating tumor response: RECIST and beyond.Biomarker research · 2021Review
- The Role of Non-Gaussian Models of Diffusion Weighted MRI in Hepatocellular Carcinoma: A Systematic Review.Journal of clinical medicine · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Differentiating between cancerous tissue and healthy liver parenchyma could represent a challenge with the only conventional Magnetic Resonance (MR) imaging. Diffusion weighted imaging (DWI) exploits different tissue characteristics to conventional Magnetic Resonance Imaging (MRI) sequences that enhance hepatocellular carcinoma (HCC) detection, characterization, and post-treatment evaluation. Detection of HCC is improved by DWI, infact this technology increases conspicuity of lesions that might otherwise not be identified due to obscuration by adjacent vessels or due to low contrast between the lesion and background liver. It is important to remember that DWI combined with contrast-enhanced MRI has higher sensitivity than DWI alone, and that some patients are not eligible for use of contrast on CT and MRI; in these patients DWI has a prominent role. MRI has advanced beyond structural anatomic imaging to now showing pathophysiologic processes. DWI is a promising way to characterize lesions utilizing the inherent contrast within the liver and has the benefit of not requiring contrast injection. DWI improves detection and characterization of HCC. Proposed clinical uses for DWI include: assessing prognosis, predicting response, monitoring response to therapy, and distinguishing tumor recurrence from treatment effect. Ideally, DWI will help risk stratify patients and will participate in prognostic modeling.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.